Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01160822 · ClinicalTrials.gov registry record · Phase 2
To Determine the Safety, Tolerability, Pharmacokinetics and Effect on Pain of a Single Intra-articular Administration of Canakinumab in Patients With Osteoarthritis in the Knee
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 169
- Enrollment target
NCT01160822 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 169 participants.
The verdict
NCT01160822, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 169 participants
- Enrollment target
Study Summary
The purpose of this study was to determine whether, in patients with mild to moderate knee osteoarthritis, canakinumab is safe and tolerable when injected intra-articularly.
Interventions
- DRUG Naproxen
- BIOLOGICAL Canakinumab
- DRUG Placebo to canakinumab
- DRUG Placebo to Naproxen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 169 participants |
| Start Date | 2010-04 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01160822
The ClinicalTrials.gov registry entry for NCT01160822 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 169 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Naproxen is the first listed.
NCT01160822 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01160822 about?
NCT01160822 is a clinical study titled "To Determine the Safety, Tolerability, Pharmacokinetics and Effect on Pain of a Single Intra-articular Administration of Canakinumab in Patients With Osteoarthritis in the Knee". The purpose of this study was to determine whether, in patients with mild to moderate knee osteoarthritis, canakinumab is safe and tolerable when injected intra-articularly.
What is the current status of trial NCT01160822?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 169 participants. The study started on 2010-04. Estimated completion is 2011-07.
What interventions are being tested in trial NCT01160822?
The interventions under investigation include: Naproxen (DRUG), Canakinumab (BIOLOGICAL), Placebo to canakinumab (DRUG), Placebo to Naproxen (DRUG).
Who is sponsoring clinical trial NCT01160822?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.